DE69201472D1 - Verhinderung der von Osteoklasten verursachten Knochenresorption durch Verwendung von substituierten Phenylderivaten. - Google Patents

Verhinderung der von Osteoklasten verursachten Knochenresorption durch Verwendung von substituierten Phenylderivaten.

Info

Publication number
DE69201472D1
DE69201472D1 DE69201472T DE69201472T DE69201472D1 DE 69201472 D1 DE69201472 D1 DE 69201472D1 DE 69201472 T DE69201472 T DE 69201472T DE 69201472 T DE69201472 T DE 69201472T DE 69201472 D1 DE69201472 D1 DE 69201472D1
Authority
DE
Germany
Prior art keywords
osteoclasts
prevention
substituted phenyl
bone resorption
phenyl derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69201472T
Other languages
English (en)
Other versions
DE69201472T2 (de
Inventor
Melissa S Egbertson
Robert J Gould
George D Hartman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE69201472D1 publication Critical patent/DE69201472D1/de
Publication of DE69201472T2 publication Critical patent/DE69201472T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69201472T 1991-08-09 1992-08-05 Verhinderung der von Osteoklasten verursachten Knochenresorption durch Verwendung von substituierten Phenylderivaten. Expired - Fee Related DE69201472T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/742,970 US5204350A (en) 1991-08-09 1991-08-09 Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives

Publications (2)

Publication Number Publication Date
DE69201472D1 true DE69201472D1 (de) 1995-03-30
DE69201472T2 DE69201472T2 (de) 1995-09-14

Family

ID=24986981

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69201472T Expired - Fee Related DE69201472T2 (de) 1991-08-09 1992-08-05 Verhinderung der von Osteoklasten verursachten Knochenresorption durch Verwendung von substituierten Phenylderivaten.

Country Status (5)

Country Link
US (1) US5204350A (de)
EP (1) EP0528587B1 (de)
JP (1) JPH0747537B2 (de)
CA (1) CA2075612A1 (de)
DE (1) DE69201472T2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2186695A (en) * 1994-03-18 1995-10-09 Diatech, Inc. Piperidyl-4-substituted thyrosine derivatives as scintigraphic imaging agents for the diagnosis of thrombosis
WO1995032710A1 (en) * 1994-05-27 1995-12-07 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
PT796855E (pt) 1996-03-20 2002-07-31 Hoechst Ag Inibicao da reabsorcao nos ossos e antagonistas de vitronectina
EP0925063A4 (de) 1996-07-01 2000-12-27 Lilly Co Eli Blutzuckersenkende und lipidsenkende verbindungen
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19629817A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
WO1998015278A1 (en) * 1996-10-07 1998-04-16 Smithkline Beecham Corporation Method for stimulating bone formation
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
DE19653647A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653645A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
EP0933367A1 (de) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Acylguanidin Derivate als Inhibitoren von Knochenaufsauge und als Vitronectin Rezeptor Antagonisten
US6313119B1 (en) 1998-01-23 2001-11-06 Adventis Pharma Deutschland Gmbh Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
EP0960882A1 (de) * 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituiertre Acylguanidine und ihre Verwendung als Knochenresorptionhemmer und als Vitronectinrezeptor-Antagoniste
CA2338275A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
US6204282B1 (en) 1998-11-30 2001-03-20 Schering Corporation Benzimidazole compounds that are vitronectin receptor antagonists
EP1028114A1 (de) 1999-02-13 2000-08-16 Aventis Pharma Deutschland GmbH Neue Guanidin-Derivate als Inhibitoren der Zelladhäsion
CN1374863A (zh) 1999-07-21 2002-10-16 惠氏公司 αvβ3整联蛋白的双环选择性拮抗剂
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
EP1108721A1 (de) 1999-12-15 2001-06-20 Aventis Pharma Deutschland GmbH Thienylalaninderivate als Inhibitoren der Zelladhäsion
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
DK2222636T3 (da) 2007-12-21 2013-06-03 Ligand Pharm Inc Selektive androgenreceptormodulatorer (SARMS) og anvendelser deraf
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3365492D1 (en) * 1982-01-27 1986-10-02 Schering Ag Diphosphonic acid derivatives and pharmaceutical preparations containing them
US5055451A (en) * 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
CA2033928A1 (en) * 1990-01-11 1991-07-12 Masahiko Sato Compositions and methods for inhibiting osteoclast cellular adhesion to bone
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
DE69201472T2 (de) 1995-09-14
US5204350A (en) 1993-04-20
EP0528587B1 (de) 1995-02-22
CA2075612A1 (en) 1993-02-10
JPH0747537B2 (ja) 1995-05-24
JPH0656663A (ja) 1994-03-01
EP0528587A1 (de) 1993-02-24

Similar Documents

Publication Publication Date Title
DE69201472D1 (de) Verhinderung der von Osteoklasten verursachten Knochenresorption durch Verwendung von substituierten Phenylderivaten.
DE69201471D1 (de) Verhinderung der durch Osteoklasten verursachten Knochenresorption durch aminoalkylsubstituierte Phenylderivate.
ATE227567T1 (de) Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
ATE269290T1 (de) Benzoylderivate
DE59100762D1 (de) Verwendung von Alkylcarbonsäure-dimethylamiden als Kristallisationsinhibitoren.
DE69200447D1 (de) Erzeugung von russen.
MX9202727A (es) Composiciones de lodo de perforacion.
DE69226763D1 (de) Härten von fluoroelastomeren
DE69202164D1 (de) Stabilisierung von Thiolenzusammensetzungen.
DE69204290D1 (de) Verwendung von 1,2,2,3,3-pentafluorpropan.
DE69104947D1 (de) Verhütung von Kesselstein.
DE59209936D1 (de) Verwendung von Acetalen
DE59001751D1 (de) Verwendung von di-styryl-phenyl-triglykolether als kristallisationsinhibitor.
ATE66675T1 (de) Stickstoffhaltige heterozyklische verbindungen.
FI923163A0 (fi) Foerfarande foer taetning av fogar i byggnader.
DK0642506T3 (da) Heterocyclisk disubstituerede sulfonaminocarbonylforbindelser
FI925172A0 (fi) Anordning foer reglering av luftstroemskraften i en vaermeanordning
DE69231883T2 (de) 4-(1,1-Dialkoxycarbonyl-Alkyl)Azetidin-2-on-Derivate zur Herstellung von 4-(1-Carboxy-Alkyl)Azetidin-2-on-Derivaten
DE3851386D1 (de) Verwendung von Glycanen als antivirale Verbindungen.
FI943119A0 (fi) Heterosyklisellä renkaalla substituoituja bentsyyliamiinijohdannaisia retrovirusvastaisina yhdisteinä
DE69205742D1 (de) Keramisches Spielausgleichselement.
DE69205983D1 (de) Beschichtung von substraten.
MX9202320A (es) Composiciones cohesivas.
DE69221897T2 (de) Herstellung von 2-(pyridyl)ethyl substituierte phosphor-verbindungen
DE69205986D1 (de) Zusammensetzung von fluorwasserstoffsäure.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee